Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berke
It's a case of so far, so good for BlueRock Therapeutics' first clinical trial of Parkinson's disease therapy bemdaneprocel, with no major safety issues reported after a y
Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinic
Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people
Bayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes a treatment for Parkinson’s disease.
UK Prime Minister Keir Starmer has promised the biggest 'reimagining' of the NHS in its history but stressed there would be no more funding without sweeping reforms.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo